Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mariano Severgnini"'
Autor:
Jiani Hu, Khanh T. Do, Geoffrey I. Shapiro, Emily M. Thrash, Claire Manuszak, Anita Giobbie-Hurder, Allison Powers, Sarah Kelland, Adrienne de Jonge, Mariano Severgnini
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2991-3000
Checkpoint kinase 1 (CHK1) has dual roles in both the DNA damage response and in the innate immune response to genotoxic stress. The combination of CHK1 inhibition and immune checkpoint blockade has the potential to enhance anti-tumoral T-cell activa
Autor:
Donald P. Lawrence, Kathleen L. Pfaff, Kristen Felt, Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott, David F. McDermott, Evisa Gjini, Mariano Severgnini, Jacquelyn O. Wolff, Matthew Nazzaro, Ryan J. Sullivan, Rizwan Haq, Scott J. Rodig, F. Stephen Hodi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.
Autor:
Jonathan D. Schoenfeld, Mizuki Nishino, F. Stephen Hodi, Raymond H. Mak, Michael Manos, Mariano Severgnini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Pneumonitis is a potential consequence of both lung-directed radiation and immune checkpoint blockade (ICB), particularly treatment with PD-1/PD-L1 inhibitors. Significant morbidity and mortality can result, and severe pneumonitis attribut
Autor:
Jared Woods, Hiroshi Nakashima, David A. Reardon, Sean E. Lawler, Sascha Marx, Anita Giobbie-Hurder, Yu Zeng, Patrick Y. Wen, E. Antonio Chiocca, Jessica Dwyer, Daniel Triggs, Mario L. Suvà, Isaac Soloman, Scott J. Rodig, Kai W. Wucherpfennig, Francesca Barone, Simon Gritsch, William Pisano, Eudocia Q. Lee, Nathan Mathewson, Paul Peter Tak, Abigail Tianai Zhang, Estuardo Aguilar-Cordova, Brian W. Guzik, James Grant, Mariano Severgnini, Keith L. Ligon, Laura K. Aguilar, David Krisky
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRecurrent high-grade glioma (HGG) represents a significant clinical unmet need with expected survival between 6 to 9 months. Oncolytic viruses are a new therapeutic approach for solid tumors that deploy oncolytic activity combined with loca